Adult Epilepsy Treatment

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

Fewer than 1 in 10 patients achieves seizure freedom with an anti-seizure medication (ASM) after 2 or more failures

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events^2,3

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^4,5

Epilepsy (US) – The VNS Therapy System is indicated for use as an adjunctive therapy in reducing thefrequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

VNS Therapy^™ Safety Profile

The most common side effects of VNS Therapy include:

Hoarseness
Shortness of breath
Sore throat
Coughing

These side effects generally only occur during stimulation and usually decrease over time.

Infection is the most common side effect of the procedure.

You can find more safety information here.

References: 1. Thurman DJ, Logroscino G, Beghi E, et al. Epilepsia. 2017;58(1):17-26. 2. Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24-31. 3. St Louis EK. Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr Neuropharmacol. 2009;7(2):106-114. 4. Alsfouk BAAA, Brodie MJ, Walters M, et al. JAMA Neurol. 2020;77(5):574-581. 5. Chen Z, Brodie MJ, Liew D, et al. JAMA Neurol. 2018;75(3):279-286. 6. Hamilton P, Soryal I, Dhahri P, et al. Seizure. 2018;58:120-126. 7. Elliott RE, Morsi A, Tanweer O, et al. Epilepsy Behav. 2011;20(3):478-483. 8. Data on file. Survey Report. LivaNova USA, Inc. Houston, TX. October 2021. 9. Englot DJ, Hassnain KH, Rolston JD, et al. Epilepsy Behav. 2017;66:4-9. 10. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415 418. 11. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX. 12. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735. 13. Data on file. E-36, E-37 Pooled Calculations. LivaNova USA, Inc. Houston, TX. 2015

Medication alone is not enough when managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events^2,3

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^4,5

The sooner you act, the more likely you are to mitigate the serious consequences of DRE

VNS Therapy™ Can De-Intensify Seizures and Provide Improvements in Seizure Control⁶*

VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years

In a survey of 200 VNS Therapy™ patients and caregivers⁸:

As soon as you identify DRE in a patient, discuss the next intervention options including VNS Therapy

Improvements in quality-of-life confirmed across 2 prospective, multicenter, clinical trials (E-36) and (E-37)¹³

Empower your patients and discuss VNS Therapy™ earlier

VNS Therapy^TM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.^10,11

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.^10,12 Infection is the most common complication of the procedure.¹¹

VNS Therapy™ has no neurotoxic effects or drug interactions^10,11

VNS Therapy^™ Safety Profile

Access resources to support your practice and patients

Hear patient stories

Choose a country

For ALL other countries, please click here.

Medication alone is not enough when managing drug-resistant epilepsy

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom1

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events2,3

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years4,5

The sooner you act, the more likely you are to mitigate the serious consequences of DRE

VNS Therapy™ Can De-Intensify Seizures and Provide Improvements in Seizure Control6*

VNS Therapy® response improves over time with a 76% mean reduction in seizures at 10 years

In a survey of 200 VNS Therapy™ patients and caregivers8:

As soon as you identify DRE in a patient, discuss the next intervention options including VNS Therapy

Improvements in quality-of-life confirmed across 2 prospective, multicenter, clinical trials (E-36) and (E-37)13

Empower your patients and discuss VNS Therapy™ earlier

VNS TherapyTM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.10,11

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.10,12 Infection is the most common complication of the procedure.11

VNS Therapy™ has no neurotoxic effects or drug interactions10,11

VNS Therapy™ Safety Profile

Access resources to support your practice and patients

Hear patient stories

Choose a country

For ALL other countries, please click here.

Patients with poorly controlled epilepsy are at more than a 10× greater risk of premature death versus those who achieve seizure freedom¹

ASM intolerance is one of the strongest and most consistent negative predictors of QoL for patients with DRE and is associated with behavioral and adverse events^2,3

Rates of intolerable adverse effects and seizure freedom with ASMs have been stagnant despite 12+ medications being approved in the last 30 years^4,5

VNS Therapy™ Can De-Intensify Seizures and Provide Improvements in Seizure Control⁶*

In a survey of 200 VNS Therapy™ patients and caregivers⁸:

Improvements in quality-of-life confirmed across 2 prospective, multicenter, clinical trials (E-36) and (E-37)¹³

VNS Therapy^TM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.^10,11

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.^10,12 Infection is the most common complication of the procedure.¹¹

VNS Therapy™ has no neurotoxic effects or drug interactions^10,11

VNS Therapy^™ Safety Profile